Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Glioblastoma 5Astrocytoma 5Gliosarcoma 4Brain Neoplasms 4Oligodendroglioma 2Medulloblastoma 2Glioma 2Ependymoma 2Central Nervous System Neoplasms 2Triple Negative Breast Neoplasms 1Spinal Cord Neoplasms 1Rhabdoid Tumor 1Optic Nerve Glioma 1Neuroectodermal Tumors, Primitive 1Nervous System Neoplasms 1Neoplasm Metastasis 1Familial ependymoma 1Choroid Plexus Neoplasms 1Central Nervous System Diseases 1Breast Neoplasms 1Brain Diseases 1

Interventions

Temozolomide 159Bevacizumab 69Radiotherapy 68Magnetic Resonance Spectroscopy 68Irinotecan 31Surgical Procedures, Operative 27Radiation 24Carboplatin 23Specimen Handling 20Carmustine 20Blood Specimen Collection 20Nivolumab 19Aminolevulinic Acid 18Biopsy 17Lomustine 16pembrolizumab 13Radiotherapy, Intensity-Modulated 13Cyclophosphamide 13trametinib 12fluorodopa F 18 12X-Rays 12Radiosurgery 12Erlotinib Hydrochloride 12Topotecan 11Everolimus 11Magnetic Resonance Imaging 10IL13-PE38 10dabrafenib 9Etoposide 9Drug Therapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Glioma × veliparib × CNS × Clear all
NCT03581292 2026-05-27

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

National Cancer Institute (NCI)

Phase 2 Active not recruiting
38 enrolled 13 charts
CNS

Astrocytoma, Glioblastoma, Glioma

NCT01026493 2017-07-02

Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma

Radiation Therapy Oncology Group

Phase 1/2 Completed
257 enrolled 16 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡